← Inventiva (ALCUR.PA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Inventiva (ALCUR.PA)
Biotechnology · market cap $15M · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
2
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Inventiva (ALCUR.PA) is a small French biotech with 71 employees and a market cap of approximately $17M, developing IVA337, a Phase 3 asset targeting Non-Alcoholic Steatohepatitis (NASH). The company has no upcoming catalysts on the calendar and limited disclosed financial or ownership data, creating a thin information environment for investors.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| IVA337 | Phase 3 | Non-Alcoholic Steatohepatitis (NASH) |
| Lanifibranor | Phase 2 | Nonalcoholic Fatty Liver Disease (NAFLD) |
Price & technical context
3-month
-24.5%
6-month
-28.6%
12-month
-45.9%
52-wk range
$1.88–$3.77
vs 50-day MA
-18.3%
vs 200-day MA
-25.6%
Realized vol
52.8%
Max drawdown
-68.5%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ALCUR.PA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.